

1 Title: Sickle hemoglobinopathy research in Zimbabwe and Zambia (SHAZ): Protocol for setting  
2 up an international Sickle Cell Disease registry

3

4 Short title: Sickle Cell Disease Registry in Zimbabwe and Zambia Protocol

5

6 Patience Kuona<sup>1#a\*</sup>, Gwendoline Q Kandawasvika<sup>1#a¶</sup>, Catherine Chunda-Liyoka<sup>2#b¶</sup>, Ian M  
7 Ruredzo<sup>3#a</sup>, Pauline M Sambo<sup>2#b</sup>, Pamela Gorejena-Chidawanyika<sup>4#a</sup>, Hamakwa M Mantina<sup>5#b</sup>,  
8 Takudzwa J Mtisi<sup>3#a</sup>, Cynthia Phiri<sup>2#b</sup>, Lawson Chikara<sup>1#a</sup>, Natasha M Kaweme<sup>5#b</sup>, Exavior  
9 Chivige<sup>1#a</sup>, Jombo Namushi<sup>2#b</sup>, Tendai Maborekeke<sup>3#a</sup>, Uma H Uthale<sup>6,#c</sup> and Collen  
10 Masimirembwa<sup>7#a</sup>

11

12 <sup>1</sup>Department of Child, Adolescent and Women's Health, University of Zimbabwe Faculty of  
13 Medicine and Health Sciences, Harare, Zimbabwe

14

15 <sup>2</sup>University Teaching Hospitals- CH & Department of Paediatric Haematology and Infectious  
16 Diseases, University of Zambia School of Medicine, Lusaka, Zambia

17

18 <sup>3</sup>Department of Laboratory Diagnostic and Investigative Sciences, University of Zimbabwe  
19 Faculty of Medicine and Health Sciences, Harare, Zimbabwe

20

21 <sup>4</sup>Department of Internal Medicine, University of Zimbabwe Faculty of Medicine and Health  
22 Sciences, Harare, Zimbabwe

23

24 <sup>5</sup>Department of Haematology, University Teaching Hospitals- Adult, Lusaka, 2Zambia

25

26 <sup>6</sup>Department of Paediatrics, McMaster University, Ontario, Canada

27

28 <sup>7</sup>African Institute of Biomedical Sciences and Technology, Wilkins Hospital, Harare, Zimbabwe

29

30 <sup>#a</sup> SHAZ program University of Zimbabwe, Harare, Zimbabwe

31 <sup>#b</sup> SHAZ program University Teaching Hospitals, Lusaka, Zambia

32 <sup>#c</sup> McMaster Children's Hospital, Hamilton, Ontario, Canada

33

34

35 \* Corresponding Author

36 E-mail: [patiekuona@gmail.com](mailto:patiekuona@gmail.com) (PK)

37

38

39 ¶ These authors contributed equally to this work.

40

## 41 Abstract

42 Of the 500 000 children born with sickle cell disease annually, most cases occur in Africa,  
43 contributing to significant morbidity and mortality associated with limited sickle cell disease  
44 (SCD) health outcomes data and reduced access to therapeutic plus preventive care. We aim to  
45 develop and manage a standardized electronic SCD registry, establish consistent standards of care

46 (SoC) for patients, improve the SCD research and biobanking capacity in Zimbabwe and Zambia.  
47 This five-year program employs mixed methods that include infrastructure and skilled manpower  
48 capacity building of SCD clinics, registry, biobanking, cohort and implementation science  
49 research studies to improve SCD treatment outcomes. We are collaborating with the  
50 SickInAfrica consortium (Ghana, Mali, Nigeria, Tanzania, Uganda, and South Africa), the  
51 African Institute of Biomedical Sciences and Technology (AiBST) and St Jude's Children  
52 Research Hospital. We established the SCD registry in Zimbabwe and Zambia for children and  
53 adult patients enrolling 1796/4000 (45%) participants to date. We are participating in  
54 SickInAfrica consortium research activities, training health workers and educating SCD patient  
55 communities on SoC. This collaboration with African researchers, policymakers, health workers,  
56 and SCD patient communities will improve uptake of SCD SoC and increase our research capacity.  
57

## 58 **Introduction and background**

59 Sickle Cell Disease (SCD) is a heterogeneous multi-organ disorder characterized by the presence  
60 of an abnormal oxygen carrier, hemoglobin S (HbS)[1]. Globally, the distribution of the sickle cell  
61 gene mirrors the geographical distribution of malaria[2]. Population migration has resulted in the  
62 spread of SCD beyond tropical regions including Southern Africa which was historically thought  
63 to have a low prevalence[3]. An estimated 500,000 children are born with the condition in the  
64 world every year with 80% of these births occurring in Africa[4]. SCD significantly contributes to  
65 under-five mortality in Africa and globally[5]. It is estimated that 50-90% of children with SCD  
66 in Africa die before their 5th birthday[6]. Very few children in Africa survive beyond 18 years of  
67 age and those who survive into adulthood have premature mortality due to end organ damage [7]  
68 e. Despite the high burden of SCD in Africa, there is limited data on the prevalence and incidence  
69 of the disease and its health outcomes. There are limited appropriate and context-specific clinical  
70 guidelines and policies for the care of affected individuals in Africa. There is also inadequate  
71 uptake of evidence-based preventive and therapeutic practices that have reduced morbidity and  
72 mortality in high-income countries[8,9].  
73

74 Historically, HbS was considered to be of low prevalence in Southern Africa but the prevalence of  
75 SCD has increased over the years due to migration[3]. Zimbabwe is estimated to have received  
76 close to one million migrants from countries with a high prevalence of SCD and with  
77 approximately 100,000 being HbS carriers[3]. A 2010 modeling study estimated that the frequency  
78 of the HbS allele in Zimbabwe was 0.021 compared to 0.171 in Nigeria, 0.112 in Zambia, 0.074  
79 in Tanzania, and 0.003 in South Africa[10]. Another modeling study in 2010 estimated that 534  
80 babies were born with SCD in Zimbabwe with the majority dying undiagnosed early in life[11].  
81 An investigation of beta-globin gene haplotypes in bio-banked samples of three cohorts from  
82 Malawi, South Africa, and Zimbabwe demonstrated that 12% of 50 healthy unrelated participants  
83 from Zimbabwe were carriers of the Hb S gene[12].  
84

85 In Zambia, SCD is most common in the northern region bordering the Democratic Republic of  
86 Congo (DRC) where the sickle cell trait (SCT) rate was reported to be 17.5%[13,14]. A more  
87 recent study by Mkushi and Serenje reported a prevalence of 15.5% of SCT and 3.4% of SCD  
88 [15]. The precise prevalence of SCD in Zambia remains unknown due to limited epidemiological  
89 surveys that have been conducted. In 2017, SCD patients accounted for 12% of the all-cause  
90 hospital admissions at University Teaching Hospital (UTH) in Zambia[16]. SCD was ranked

91 fourth of the top five causes of mortality and was amongst the top 10 reasons for seeking medical  
92 attention at the University Teaching Hospitals - Children's Hospital (UTHs - CH) in Lusaka the  
93 capital city of Zambia (Unpublished communication with Dr Catherine Chunda-Liyoka). Lusaka  
94 is in the central part of Zambia and the SCD numbers are likely to be higher in the northern regions  
95 of Zambia.

96  
97 SCD is therefore, a significant cause of morbidity and mortality in children and young adults in  
98 Zimbabwe and Zambia. However, there is paucity of data to allow for accurate characterization of  
99 the epidemiology and policy formulation accompanied by limited capacity for diagnosis and  
100 clinical management for individuals with SCD. There are also limited national policies or  
101 programs to guide surveillance, diagnosis, and management of SCD that have been formulated or  
102 implemented. Zambia launched its national clinical guidelines and a pilot newborn screening  
103 program for SCD in 2020[17]. In addition, there is a need for an SCD registry and research  
104 program to inform future practices and policies in the two countries.

105  
106 The Sickle Hemoglobinopathy reseArch in Zimbabwe and Zambia (SHAZ) program's  
107 overarching goal is to establish a sustainable infrastructure and operation aimed at addressing the  
108 paucity of data that currently exists for SCD in the two countries. In addition, the SHAZ program  
109 aims to integrate common SCD management guidelines, develop evidence-based care practices,  
110 and bring these practices to the bedside via the conduct of implementation science research. Our  
111 collaborators include six countries within the SickleInAfrica consortium (Ghana, Mali, Nigeria,  
112 Tanzania, Uganda, and South Africa) (<https://www.sickleinafrica.org/>), the African Institute of  
113 Biomedical Sciences and Technology (AiBST) and St Jude's Children Research Hospital in the  
114 USA. The SHAZ program specific objectives are to:

- 115 1. Develop and manage an electronic SCD registry with standardized and rigorous clinical  
116 follow-up within Zimbabwe and Zambia recruiting at least 4000 participants in 5 years
- 117 2. Establish consistent standards of care for patients with SCD in Zimbabwe and Zambia
- 118 3. Capacitate investigators to design research on priority areas in SCD relevant to Zimbabwe  
119 and Zambia.
- 120 4. Establish and improve the biobanking capacity of SCD biospecimens..

121 We highlight the SHAZ program protocol and lessons learnt in establishing a SCD registry in  
122 Zimbabwe and Zambia, two countries within the SickleInAfrica consortium.

123

## 124 **Materials and methodology**

### 125 **Study design**

126 The SHAZ program involves mixed methods approaches (qualitative and quantitative), that  
127 include infrastructure & skilled manpower capacity building of the SCD clinics, a prospective  
128 observational registry, biobank, cohort studies to evaluate the effect of various factors in the  
129 treatment and management of SCD, and implementation science studies to improve outcomes of  
130 SCD. This is a 5-year program extending from 01 May 2021 to 30 April 2026.

131

## 132 **Study setting**

133 Parirenyatwa Teaching Hospital (PTH) in Zimbabwe and UTHs in Zambia are specialized  
134 university teaching hospitals that offer a comprehensive care package for children and adults with  
135 SCD. Additionally, each hospital has a relatively large bed capacity of 2000.

136 Zimbabwe: There are 6 implementation sites. The main site is PTH SCD clinic which was the  
137 first site to implement the SHAZ program in May 2021. There are 5 outreach sites: Bindura  
138 Provincial and Mount Darwin District hospitals in Mashonaland Central Province, Murehwa and  
139 Mutoko District hospitals in Mashonaland East Province, and Chinhoyi Provincial Hospital in  
140 Mashonaland West Province.

141 Zambia: There is one site at the UTHs SCD center in Lusaka.

142 The SHAZ sites have been implementing the registry recruitment, the research projects and  
143 standards of care for SCD since project inception. All the sites offer inpatient and outpatient  
144 services to patients with SCD.

145

## 146 **SHAZ registry study population**

147 SCD patients from the selected sites in Zimbabwe and Zambia are eligible for recruitment into the  
148 SCD registry. The registry recruits all the age groups across the lifespan.

149 Inclusion criteria

150 Any participant giving their written informed consent/assent, screened and found to have two  
151 abnormal copies of the hemoglobin gene, with at least one of the two genes resulting in production  
152 of hemoglobin S:

- 153 ●
- 154 ● Hb SS – sickle cell anaemia
- 155 ● Hb SC
- 156 ● Hb S $\beta$ 0 thalassemia
- 157 ● Hb S $\beta$ + thalassemia
- 158 ● Hb SD
- 159 ● Hb SE

160 We are also including participants with

- 161 ● Sickle cell trait (Hb AS or another trait variant)

162 Exclusion criteria:

- 163 ● Absence of hemoglobin S
- 164 ● Patients not giving their written informed consent/assent

165 Only the participants with SCD contribute to the SickleinAfrica consortium registry while the  
166 participants with SCT contribute to the local registry data.

167

168 Sample size:

169 Registry aims to recruit at least 4000 participants with SCD in the 5 years of the study.

170

## 171 **Study procedures**

172 Permission was obtained from the Ministries of Health (MOH) to work with PTH, UTHs,  
173 Provincial and District health teams to sensitize health workers and raise awareness of the SHAZ  
174 program and SCD registry. The Sickle Cell Anaemia Trust in Zimbabwe (SCATZ) and Zambia  
175 Sickle Cell Anaemia Society (ZSCAS) are the patient organizations that assist with community  
176 engagement activities raising awareness of the SCD registry project and the SHAZ program.

177 Community awareness campaigns have been done using traditional, digital and visual media as  
 178 well as community events commemorating SCD. Potential study participants are approached in  
 179 the general pediatric and adult medical wards; the accident and emergency departments; maternity,  
 180 antenatal and perinatal service units; surgical wards and the outpatient’s clinics (including the  
 181 vaccination and growth monitoring units).

182

183 **Objective 1 and 2**

184 We have set up the SCD center of excellence at PTH and consolidated the one at UTH. We  
 185 developed the SCD Research Electronic Data Capture (REDCap) database[18] by adopting the  
 186 Sickle Cell Disease Ontology (SCDO) (<https://scdontology.h3abionet.org/>) and SIA data  
 187 elements([https://www.sickleinafrica.org/SIA\\_data\\_elements](https://www.sickleinafrica.org/SIA_data_elements)). All SCD participants confirmed  
 188 SCD by their routine health service providers are approached to seek written consent to participate  
 189 in the SCD registry. Acceptable laboratory confirmatory diagnostic tests performed before  
 190 recruitment include sickle cell screen, point of care tests, electrophoresis, isoelectric focusing,  
 191 High-performance liquid chromatography (HPLC) and / or molecular tests. This is an  
 192 observational longitudinal registry with no interventions planned which collects information on  
 193 demographics, clinical information, drug use, treatment and outcomes of children and adults with  
 194 SCD (see Table 1).

195

196 Table 1. SHAZ registry data elements adopted from the SCDO and SickleinAfrica.

Data element name		Number of data elements
Core data elements		66
Extended demographics		16
	Anthropometrics	19
	Medical history SCD complications	32
	medical history 6month pain episodes	6
	Medical history 12month pain episodes	3
	Medical history stroke	106
	Medical history arterial and venous disease	23
	Medical history kidney disease	5
	Medical history epilepsy	1
	Medical history transfusion	3
	Medical history blood pressure	12
	Alcohol	9
	Smoking status	32
	Lifetime drug use	84
	Laboratory results complete blood count	13
	Laboratory results kidney function assay	9
	Laboratory results liver function assay	54
	Additional laboratory results	186
	Therapeutics reception	1

	Therapeutics prescription medication	9
	Therapeutics over counter medication	10
	Therapeutics past and present pain medication	26
	Quality of life and care	466
	Phenotype	242
	Genotype	39
	Gross motor skills child	4

197 Note: Only age appropriate data will be collected for one individual.

198  
199 The SHAZ team consisting of the coordinator, outreach workers, and data capture clerks work  
200 closely with the recruitment site teams to ensure that participant-related activities and data are  
201 promptly entered into the database using mobile devices. Strategic health workers' training in  
202 partnership with the Ministry of Health (MOH) at the two hospitals (PTH & UTH) and outreach  
203 sites are continuously being carried out by the SHAZ team to raise awareness of the SCD registry  
204 program. All SHAZ recruitment sites are being trained on SCD standards of care adopted from  
205 the SicklenInAfrica Consortium[19]  
206 ([https://sadacc.org/sites/default/files/SPARCo\\_SoC\\_SCD\\_GuidelinesR\\_Aug2023.pdf](https://sadacc.org/sites/default/files/SPARCo_SoC_SCD_GuidelinesR_Aug2023.pdf)), as well as  
207 the PEN-Plus program(<https://www.ncdipoverty.org/sickle-cell-disease>) in collaboration with  
208 policymakers in the MOH.

209  
210 **Objectives 3 and 4**  
211 Since the inception of the SHAZ project, we have been working to come up with four consortium-  
212 wide studies in the areas prioritized by the SIA consortium countries directly funded by the NIH  
213 NHLBI awarded grant. There are two cohort studies on pharmacogenomics of pain management  
214 and malaria in children with SCD. There are two implementation studies on newborn screening  
215 and penicillin/hydroxyurea use. The four protocols will be implemented by all consortium  
216 countries once finalized. We also have been working on various local site studies in both Zambia  
217 and Zimbabwe collaborating with MOH, local academic institutions, and other funders. We set up  
218 the biorepository for specimen biobanking linked to the proposed cohort and implementation  
219 science studies in collaboration with the AiBST in Zimbabwe and the UTH laboratory in Zambia.

## 220 221 **Retention of participants in the SCD registry**

222  
223 The following retention strategies are being applied to retain patients in the registry[20,21]:

### 224 225 **Barrier-reduction retention methods**

- 226 • Ensuring investigators and support staff are well trained in research methodology, good  
227 clinical practice (GCP), and ethics
- 228 • Ensuring consistent research staff and hiring staff who can speak the language of the  
229 participants as well as understand their cultural values
- 230 • Making use of expert SCD patients to mobilize the community and improve community  
231 participation.

- 232 • Providing SCD education and awareness campaigns and stressing the benefits of
- 233 participating in long-term cohorts in the communities from which we recruit participants
- 234 • Running a pilot test of the registry
- 235 • Establishing simple and efficient procedures for data collection. Limiting the number of
- 236 visits to recruitment and an annual visit for data collection.
- 237 • Providing both on-site and telephonic longitudinal data collection to cater to different
- 238 participants' preferences. At recruitment, participants are asked to state the method they
- 239 prefer for communication with the study staff [in person, telephone/cellphone -voice or
- 240 SMS or social media platforms].
- 241 • Ensuring confidentiality and privacy for participants.
- 242 • Reimbursing travel costs to participants scheduled for data collection and recognizing the
- 243 milestones reached in each year of the study.
- 244

### 245 **Community-building retention strategies**

- 246 • We have engaged the SCD community advocacy groups (SCATZ & ZSCAS) who
- 247 provided support letters for the grant application. We will continue to work with them as
- 248 we implement our program. We have also incorporated them into our Advisory committee
- 249 which advises the principal investigator and research team.
- 250 • Providing education and awareness campaigns on SCD for communities guided by our
- 251 ministries of health policies and regulations.
- 252

### 253 **Follow-up and participant reminder strategies**

- 254 • Using appointment cards and diaries.
- 255 • Using telephone or cellular voice or SMS reminders.
- 256 • The integration of important or required annual reviews of SCD patients such as urinalysis,
- 257 BP check, and TCD measurement.
- 258

### 259 **Tracing strategies**

- 260 • Documenting alternative contact details of participants.
- 261 • Completion of change of address forms at every visit.
- 262

## 263 **Data management**

264

### 265 **Data collection**

266 For the SHAZ registry, data is collected and entered directly into an electronic database developed

267 for the study using REDCap data capture software that is password protected to avoid data

268 compromise. REDCap is an online system that has an embedded mobile application that allows

269 offline collection of data and uploads it later using an internet connection. A data dictionary

270 provided by the SIA Data Coordination Center (DCC) was imported into REDCap. Mobile

271 REDCap data collection using tablet computers was chosen for all recruiting sites and the data

272 capturers have a code name to assist the data manager with resolving data queries. Training on the

273 registry protocol and REDCap software preceded any data collection. All enrolled participants are

274 identified using unique Participant Identifiers (PID) in the database and on data collection forms.

275 All information that identifies the participants such as their names, telephone numbers, and

276 addresses are captured on a separate Study Log kept in a secure place accessed by authorized  
277 persons only. Data collectors then upload data through an internet connection to the central server  
278 and the Data Manager confirms receipt and reviews the data to check for completeness, validity,  
279 and accuracy. If data is collected on paper forms, these forms are reviewed for completeness,  
280 accuracy and the use of skip logic before data entry directly into the SHAZ Registry database.  
281 Paper forms are stored in secure metal lockable cabinets accessed by the Study Coordinator and  
282 Principal Investigator only in both Zimbabwe and Zambia.

283  
284 All registry data is stored on a password protected local server located in a secure commercial data  
285 center in Zimbabwe and data backups are kept at the research sites at PGH and UTH with access  
286 limited to the Investigators, Study Coordinator, and Data Manager. Data backup is done on a  
287 password protected external media and stored securely at a central place with access limited to  
288 only authorized personnel. Data capturers in Zimbabwe have no access to data from Zambia and  
289 vice versa. Only the principal investigator, co-principal investigators, study coordinator, and data  
290 manager have access to data from both sites. A few data points on gender, age, and date of  
291 diagnosis are uploaded to the DCC and this is guided by a data sharing agreement signed by  
292 Zambia, Zimbabwe and DCC authorized signatories.

293  
294 Data quality checks begin during data entry as the database is designed with built-in quality control  
295 data entry checks to scan for possible errors, missing data and values out of range. To continuously  
296 improve the data quality, integrity and validity, the Data Manager does the Quality Control (QA)  
297 real-time review of every single data entry submitted to the central server daily for accuracy,  
298 completeness, timeliness, and logic or skip controls. Queries of any data discrepancy noted are  
299 sent back to the data collectors for clarification and resolution. The Data Manager produces data  
300 quality reports every week and any trends noted in the quality of data are discussed and re-training  
301 done to address recurring data errors. Software malfunction issues that arise are discussed with the  
302 DCC and the REDCap software developers.

303  
304 **Data analysis**  
305 Summary descriptive statistics will be employed to describe the participants' socio-demographic,  
306 phenotype, and genotype data as well as the prevalence and incidence of complications as we  
307 follow up with the participants throughout the study period. The proposed cohort and  
308 implementation science studies outlined will have more detailed descriptions once the full  
309 protocols are completed at the time of submission for ethics approval for each protocol.

310  
311 **Ethics**  
312 The research regulatory authorities in Zimbabwe, that is, the Joint Research Ethics Committee  
313 (JREC/202/21) and Medical Research Council of Zimbabwe (MRCZ/A/2747) provide ethical  
314 oversight of this registry and the proposed research activities. The Ministry of Health and Child  
315 Care, clinical directors, and respective provincial medical directors approved the research at the  
316 PTH and provinces.

317  
318 In Zambia, ethical approval was sought and granted by the local Research and Ethics committees,  
319 of the Excellence Research Ethics & Science Converge, (2021-May-092) and from the National  
320 Health Research Authority (NHRA00027/26/09/2023) prior to the commencement of the SHAZ



321 registry program. Permission to conduct the study was also obtained from the Ministry of Health  
 322 (MOH) and the participating institutional leadership.

323  
 324 SHAZ adopted informed consent forms (ICFs) developed by the CCC to conform with the  
 325 requirements of the local regulatory authorities. Written informed consent in the participant's  
 326 preferred language is obtained using ICFs approved by each country's ethics committee. A data  
 327 sharing agreement approved by local ethics committees and institutional leaders was implemented  
 328 between Zimbabwe and Zambia as well as between SHAZ and the Data Coordination Center. This  
 329 study is embedded in routine care, there are no physical potential risks rendered to the participants  
 330 in the registry. However, taking part in the registry may result in people knowing the participant  
 331 has sickle cell disease and there is a risk the participant may experience social discrimination which  
 332 can result in psychological distress. Psychosocial support for participants is provided by the SCD  
 333 clinicians and patient support groups. It is emphasized in the ICF that participation in the registry  
 334 is voluntary, and participants are free to refuse to participate or withdraw from the registry at any  
 335 time without loss of benefits to care.  
 336

### 337 **Timeline of the study**

338  
 339 The registry has been recruiting participants as of 1<sup>st</sup> November 2021 in Zimbabwe and 1<sup>st</sup> March  
 340 2022 in Zambia. A pilot phase was carried out in Zimbabwe from November to December 2021  
 341 and any emerging issues were resolved with the DCC. Substantive data collection began in  
 342 Zimbabwe on 3<sup>rd</sup> of January 2022 and in Zambia on the 1<sup>st</sup> of March 2022. Data collection will  
 343 end on 30<sup>th</sup> of April 2026 at the end of the funding cycle. The registry project is in the 3<sup>rd</sup> year of  
 344 implementation. Table 2 shows the timelines and evaluation metrics for the SHAZ program over  
 345 5 years. Year one was a developmental phase of establishing systems for the program linking the  
 346 two international sites in Zimbabwe and Zambia with the SickleinAfrica consortium already  
 347 established systems. The registry earnestly began recruitment in the last quarter of year one at both  
 348 sites and hopefully we will reach 50% or more recruitment by end of year 3.  
 349

350 Table 2. Timelines and evaluation of the SHAZ research activities and outcomes.

Activities	Developmental phase milestones (Year 1)	Implementation milestones (Year 2-5)	Key Metrics
<b>Establish SHAZ as an effective &amp; productive SCD-SSA Network program by leveraging expertise from long-term partners</b>			
a. Establishing a comprehensive care SCD clinic and research site for children and adults at PTH & Zambia-UTH. Establishing	The project governance structure, SCD clinics & outreach sites are established at PTH and UTHs.	Fully functional governance structure & SCD clinics are established at PTH and Zambia-UTH.	<ul style="list-style-type: none"> <li>• A functional governance structure</li> <li>• Number of SCD clinics set up</li> </ul>

outreach sites in both countries.			
b. Comprehensive training on SCD care & community engagement for the SHAZ team.	SHAZ team is trained on the consortium structure, operations and governance, SCD care & community engagement.	SHAZ team attends refresher trainings on consortium operations and governance, SCD care & community engagement.	<ul style="list-style-type: none"> <li>• Number of SHAZ leaders trained</li> <li>• Number of # trainings attended</li> </ul>
c. The SHAZ will establish robust communication infrastructure within the Zambia and Zimbabwe sites for communication with CCC, DCC, MoH and NHBLI.	Zoom/Webex/Skype are procured to facilitate quarterly meetings with CCC & DCC, MoHCC and NHBLI	20 Quarterly online meetings are conducted with CCC & DCC, MoHCC and NHBLI.	<ul style="list-style-type: none"> <li>• Number and types of procured ICT infrastructure</li> <li>• Number of online meetings conducted</li> </ul>
<b>Develop &amp; maintain an electronic SCD registry with standardized &amp; rigorous clinical follow-up</b>			
a. Coordinating with CCC and DCC to develop standardized protocols for recruiting & following up at least 4000 patients.	Standardized protocols developed by CCC for recruiting patients are adopted and at least 500 patients are recruited and followed-up on.	At least 3500 patients are recruited, enrolled and followed-up from Year 2 to Year 5.	<ul style="list-style-type: none"> <li>• Number of standardized protocols developed, adopted or adapted</li> <li>• Number of patients recruited and followed-up by the program in Zambia &amp; Zimbabwe</li> </ul>
b. A REDCap registry is created and maintained for both sites.	REDCap registry is developed in line with the CCC and DCC protocols.	The registry is routinely updated and Realtime data is captured. Data manager conducts regular data clean-ups and quality checks.	<ul style="list-style-type: none"> <li>• A functional REDCap registry with cleaned-up real time data</li> </ul>

<b>Establish &amp; evaluate consistent standards of care for SCD patients in Zimbabwe &amp; Zambia to improve patient outcomes</b>			
<p>a. Modify and adopt care policies, developed by the consortium on:</p> <p>i. New-born screening to improve SCD diagnosis</p> <p>ii. Use of prophylaxis to prevent infections</p> <p>iii. Increase Hydroxyurea use among SCD patients.</p>	<p>Locally feasible and consistent standards of care guidelines for Zimbabwe and Zambia are compiled, updated and CCC priorities are incorporated and implemented.</p>	<p>Participating sites in Zambia and Zimbabwe continue to implement revised SCD standards of care and management.</p>	<ul style="list-style-type: none"> <li>Revised standards of care documents for SCD in Zimbabwe and Zambia</li> <li>Progress reports on standards of care implementation</li> </ul>
<b>Train &amp; capacitate investigators in the design &amp; implementation of ethically sound cohort &amp; implementation research studies to address priority objectives relevant to Zimbabwe and Zambia.</b>			
<p>a. Design and conduct of 3 Cohort studies in SCD patients.</p>	<p>3 Specific cohort studies protocols developed and ethics approval obtained. Plan for implementation of studies.</p>	<p>Implementation of the 3 cohort studies is completed.</p>	<ul style="list-style-type: none"> <li>Number of studies completed</li> <li>Number of publications</li> <li>Number of findings incorporated into policy/practice</li> </ul>
<p>b. Design &amp; conduct 3 implementation studies.</p>	<p>3 Specific Implementation science protocols developed and ethics approval obtained. Plan for the implementation of studies.</p>	<p>3 Implementation Science research projects completed.</p>	
<p>c. Participate in biospecimen banking using protocols developed by CCC and DCC.</p>	<p>SHAZ technologists are trained, Standard Operating Procedures (SOPs) are developed, Laboratory and biobank is set up.</p>	<p>The laboratory and biobank are functional and being managed by trained technologists using documented SOPs.</p>	<ul style="list-style-type: none"> <li>Number of trained technologists</li> <li>SOPs document</li> <li>A functional laboratory and biobank which</li> </ul>

			meet the quality standards of the CCC and DCC
--	--	--	---

CCC Clinical Coordination Center DCC Data Coordination Center ICT Information and Communication Technologies MoH Ministry of Health NHLBI National Heart, Lung and Blood Institute PTH Parirenyatwa Teaching Hospital REDCap Research Electronic Data Capturer SCD Sickle cell disease SHAZ Sickle Hemoglobinopathy research in Zimbabwe and Zambia SOPs Standard Operating Procedures SSA Sub-Saharan Africa UTH University Teaching Hospital in Zambia

351

352 **Plans for dissemination of results**

353 Our target audience includes SCD patient communities, researchers, policy makers, non-  
354 governmental organizations and health workers. Table 3 outlines the dissemination plan for the  
355 SHAZ Program findings.

356

357 Table 3 SHAZ program dissemination plan

Target group		Oral presentations	Written presentations
SCD patient communities & patient organizations	<ul style="list-style-type: none"> <li>• ZCAS</li> <li>• SCATZ</li> <li>• Patients in the registry</li> <li>• Other patient organizations in Zimbabwe &amp; Zambia</li> </ul>	<ul style="list-style-type: none"> <li>• Dissemination meetings</li> <li>• Social networks e.g. YouTube, Instagram and X</li> </ul>	<ul style="list-style-type: none"> <li>• Press release</li> <li>• Lay summaries</li> </ul>
Policy makers	<ul style="list-style-type: none"> <li>• Ministries of health in Zambia and Zimbabwe</li> </ul>	<ul style="list-style-type: none"> <li>• Dissemination meetings</li> </ul>	<ul style="list-style-type: none"> <li>• Policy briefings</li> <li>• Press release</li> </ul>
Non-governmental organizations	<ul style="list-style-type: none"> <li>• Academic institutions</li> </ul>	<ul style="list-style-type: none"> <li>• Dissemination meetings</li> </ul>	<ul style="list-style-type: none"> <li>• Journal articles</li> <li>• Newsletters</li> <li>• Conference posters</li> </ul>
Health workers	<ul style="list-style-type: none"> <li>• Public and private institutions in</li> </ul>	<ul style="list-style-type: none"> <li>• Workshops</li> </ul>	<ul style="list-style-type: none"> <li>• Journal articles</li> <li>• Newsletters</li> </ul>

	Zimbabwe and Zambia		
Researchers	<ul style="list-style-type: none"> <li>Local, regional and international</li> </ul>	<ul style="list-style-type: none"> <li>Conference oral abstracts</li> </ul>	<ul style="list-style-type: none"> <li>Conference posters</li> <li>Journal articles</li> </ul>

358

## 359 **The current status of the SHAZ Program**

360 1. To establish SHAZ as an effective and productive program in the treatment and management of  
361 SCD:

362 The research team engaged and sensitized the policy makers and hospital administrators from both  
363 countries on the SHAZ program through an inception meeting and other forums. This has  
364 facilitated implementation of the registry, research and standard of care improvement activities in  
365 the recruitment sites. Comprehensive care SCD clinics for children and adults with robust outreach  
366 programs have been established or improved at the University of Zimbabwe PTH and UTHs in  
367 Zambia respectively. SHAZ research team and patient support groups were recruited. The team  
368 has received comprehensive protocol training and appropriate training in laboratory skills, genetic  
369 counselling, data management, clinical management of patients with SCD and community  
370 engagement. We obtained ethics clearance for the SHAZ registry project in both Zimbabwe  
371 (JREC/202/21 and MRCZ/A/2747) and Zambia (ERES 2023-Apr-005 and  
372 NHRA000006/19/12/2023). We have signed a data sharing agreement between Zimbabwe and  
373 Zambia SHAZ programs as well as with the SIA DCC at University of Cape town. We have  
374 established 4 out of the 5 outreach sites( Mutoko, Murehwa, Bindura and Mt Darwin) in Zimbabwe  
375 and are working on establishing the Chinhoyi site before the end of year 3. We participate in the  
376 SHAZ meetings: quarterly Advisory committee meetings, monthly executive committee meetings  
377 with Zambia, weekly registry data meetings and weekly site administration meetings. We are also  
378 participating in biannually SIA consortium meetings,

379 2. To develop and maintain an electronic SCD registry with standardized and rigorous clinical  
380 follow-up:

381 We adopted the SIA consortium data collection tools to recruit, enroll and follow-up at least 4,000  
382 individuals with SCD. We piloted the registry successfully in year one 3<sup>rd</sup> quarter and had recruited  
383 48% of participants by February 2024. Zambia has recruited more participants with a ration of 5  
384 to 1 to Zimbabwean numbers reflecting the difference in epidemiology of SCD in the two  
385 countries.

386 3. To establish consistent standards of care for patients with SCD in Zimbabwe and Zambia:

387 We engaged ministries of health technical departments in Zambia and Zimbabwe, evaluated  
388 existing standards of care for patients with SCD, adapted SIA consortium and PEN-Plus standards  
389 of care recommendations. We have trained 27 health workers from both countries in genomics in  
390 2022. The focus in the 5-year period is on implementing SCD newborn screening, improve use of  
391 antibiotic prophylaxis for infection prevention and increased hydroxyurea use among SCD  
392 patients.

393 4. To train and capacity build investigators in the design and implementation of ethically sound  
394 cohort and implementation research studies:

395 Our investigators and research staff have participated in training on REDCap software, research  
396 methodology for cohort and implementation science research hosted by the CCC, DCC and various

397 partners of the SIA consortium. We have participated in the selection of four SickleInAfrica cross  
398 consortium studies:

399 • Two cohort studies in the area of SCD pain management pharmacogenomics and Malaria  
400 chemoprophylaxis in children with SCD

401 • Two implementation studies on SCD newborn screening and Penicillin /Hydroxyurea use  
402 SHAZ is leading the development of the SCD pharmacogenomics of pain management study  
403 protocol while other consortium members are leading the finalization and implementation of the  
404 other studies. The SHAZ lead protocol has been submitted to SIA consortium and NIH for  
405 approval. We have also supported site specific research in Zimbabwe ( 6 students) and Zambia (x  
406 students) by masters and doctoral students.

407 5. To Establish a biobank of the SCD biospecimens : collected and documented in the SCD  
408 registry: The SHAZ program has provided additional training to laboratory scientists on  
409 biospecimen collection, storage, tracking, shipping and quality control using CCC and DCC  
410 protocols. The Biobank has well trained staff made up of 6 people with expertise in management,  
411 information technology, ethics, laboratory technologies, and logistics. The biobanking is linked to  
412 the research studies. The biobank activities are a collaboration of the SHAZ program, the AiBST  
413 and SIA consortium.

414

## 415 **Discussion**

416 The SHAZ program aims to improve SCD SoC through research collaboration with fellow African  
417 researchers, policy makers, health workers and SCD patient community groups. It is supporting  
418 innovation through research and teaching. We are on track to meet our specific objectives over a  
419 5-year period. The SHAZ registry protocol was amended in Jan 2022 after discussion at SIA  
420 consortium level to include an annual follow up for all recruited participants in the registry. Our  
421 research strategy was harmonized with the SIA consortium to streamline funding to support four(4)  
422 studies (2 cohort and 2 implementation sciences) which will generate more robust evidence on  
423 SCD management in Sub-Saharan Africa instead of the originally planned six (6) small studies.  
424 These changes though welcome has put a strain on our financial resources and we have expanded  
425 our focus to looking for local and international funders to augment our planned research activities.  
426 The SHAZ program has created opportunities to network with other SCD African researchers  
427 increasing exchange of ideas and expertise. We look forward to the establishment and signing of  
428 the SIA charter which will further cement our participation in the consortium activities and sharing  
429 of data. We also have benefitted from the CCC and DCC supporting our registry, SCD SoC and  
430 research activities through provision of monetary and non-monetary resources. We have recruited  
431 two research fellows one in each country.

432

## 433 **Strengths of the SHAZ program**

434 The SHAZ registry is an expansion of the pilot SCD registry that was set up in 2018 at the  
435 Parirenyatwa Hospital Paediatric Haematology unit for children under 18 years who have SCD.  
436 The registry involves two countries of Zimbabwe and Zambia which share a border on the Zambezi  
437 River. Through the SickleInAfrica consortium, Zimbabwe and Zambia have the unique  
438 opportunity to learn from their common and distinct experiences to enhance their work on SCD.  
439 The establishment of an electronic registry has allowed easy tracking of patients in the registry. A  
440 biobank linked to the research studies and registry for both countries was created and this will

441 serve as a reliable resource for future research. The SCD advocacy community groups in both  
442 countries are engaged in the process of ensuring support for patients and their families. The  
443 Ministries of Health in Zimbabwe and Zambia are supportive of the SHAZ program. The SHAZ  
444 program provides technical support for training of healthcare workers to ensure sustainability,  
445 improvement of SCD awareness and standards of care. The results from the registry will help to  
446 direct policy in SCD diagnosis and management prioritization in the two countries.

447  
448 Being part of the consortium has facilitated a cascade of training opportunities and activities that  
449 may not have been possible for SHAZ to conduct alone. These include SHAZ staff training in data  
450 management, genetic counselling, grant writing, research methodology and manuscript writing.  
451 The Data Coordinating Center has supported the enrolment of two research fellows in Zambia and  
452 Zimbabwe. Collaborating with the SIA consortium is facilitating the development and  
453 implementation of consortium-wide studies.

454

### 455 **Limitations of the SHAZ program**

456 The limited diagnostic and management resources for SCD consequently interfere with the  
457 identification of affected patients and the provision of appropriate standards of care. There is a  
458 need for the research program to find ways of involving other partners to augment funding received  
459 and sustain the program. The hospital-based nature of the registry facility excludes patients with  
460 asymptomatic or mild disease who do not seek care at the recruitment facilities. However, the  
461 involvement of SCD advocacy community groups and the Ministries of Health in both countries  
462 helps to increase awareness of the program. This will facilitate recruitment of patients who are not  
463 hospital-based. The inconsistency in patient follow-up diminishes the availability of follow-up  
464 data for patients and will affect treatment outcome measurement. Only 245 (28 %) of the 853  
465 recruited patients in year one have returned for the one-year follow-up visit. This has highlighted  
466 that patients tend to go to the hospital only when they have acute or chronic complications  
467 requiring urgent attention. We are working on implementing strategies to increase follow up rates.  
468 The cost of hydroxyurea and penicillin V are relatively high for most patients who reside in remote  
469 rural areas who are not formally employed. This results in some patients defaulting treatment.  
470 There is a need for the program to engage policymakers and other partners to assist in the  
471 availability of SCD medications at an affordable price. There is a need for collaborative initiatives  
472 with patients and policymakers to lobby for universal treatment for SCD similar to TB and  
473 HIV/AIDS programs since SCD is an important non-communicable disease affecting many  
474 patients in Sub-Saharan Africa. The study is only covering specific parts of the country, and this  
475 limits access for children and adults with SCD in the non-participating regions. However, we hope  
476 that engaging the policymakers will have a spillover effect with adoption of policies that will  
477 benefit all SCD patients in the two countries.

478

### 479 **Conclusion**

480 The SHAZ program in Zimbabwe and Zambia is already making an impact by engaging policy  
481 makers, SCD communities and researchers. At the end of the 5 years, the program will generate  
482 hospital based evidence of the burden of SCD in the two countries' participating sites paving way  
483 for bigger and more representative epidemiological research. The SHAZ registry is an important  
484 infrastructure which will support basic science, translational and implementation science research.

485 It is raising the awareness for SCD in the two countries and we hope this will translate to improved  
486 standards of care for patients with SCD.  
487

## 488 **Acknowledgements**

489 We would like to acknowledge the following people:

- 490 1. UZ PETRA secretariat: Antony Matsika, Thokozile Mashaah, Nhauro Mupanguri, Felix  
491 Madya, Miriro Muvoti, Caroline Tazvivinga and Tendayi Maunganidze (<https://petra.org.zw>)  
492 and Professor James Gita Hakim (posthumously) for the excellent mentorship of the SHAZ  
493 research team during the SHAZ protocol and grant writing.
- 494 2. The SHAZ advisory committee: Professor Inam Chitsike, Professor Midion Chidzonga,  
495 Professor Jonathan Matenga, Dr Nickhill Bhakta, Professor Uma Uthale, Professor Tsungai  
496 Chipato, Ms Molyn Chima from SCATZ and Ms Ketty Chunga from ZCAS our SCD  
497 community advocates for guiding us through the process of developing and implementing the  
498 SHAZ program.
- 499 3. The SHAZ research administrator Blessing Murangadzva and Data Capturer Nunurai Sphandla  
500 and Driver Mr Jackson Mwepeta for working tirelessly to ensure a smooth implementation of  
501 the SHAZ program.
- 502 4. The SIA Africa consortium for supporting the SHAZ program participation in the consortium
- 503 5. Dr Pauline Kazembe for editing our manuscript language

## 504 505 **References**

- 506 1. Kanter J, Kruse-Jarres R. Management of sickle cell disease from childhood through  
507 adulthood. *Blood Reviews*. 2013;27: 279–287. doi:10.1016/j.blre.2013.09.001
- 508 2. Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Williams TN, et al. Global  
509 distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis.  
510 *Nature Communications*. 2010;1. doi:10.1038/ncomms1104
- 511 3. Piel FB, Tatem AJ, Huang Z, Gupta S, Williams TN, Weatherall DJ. Global migration and  
512 the changing distribution of sickle haemoglobin: A quantitative study of temporal trends  
513 between 1960 and 2000. *The Lancet Global Health*. 2014;2. doi:10.1016/S2214-  
514 109X(13)70150-5
- 515 4. Thomson AM, McHugh TA, Oron AP, Teply C, Lonberg N, Vilchis Tella V, et al. Global,  
516 regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a  
517 systematic analysis from the Global Burden of Disease Study 2021. *The Lancet*  
518 *Haematology*. 2023;10: e585–e599. doi:10.1016/S2352-3026(23)00118-7
- 519 5. Wastnedge E, Waters D, Patel S, Morrison K, Goh MY, Adeloje D, et al. The global  
520 burden of sickle cell disease in children under five years of age: A systematic review and  
521 meta-analysis. *Journal of Global Health*. 2018;8. doi:10.7189/jogh.08.021103
- 522 6. Grosse SD, Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN. Sickle cell disease  
523 in Africa: A neglected cause of early childhood mortality. *American Journal of Preventive*  
524 *Medicine*. 2011;41: S398–S405. doi:10.1016/j.amepre.2011.09.013



- 525 7. Wonkam A, Makani J. Sickle cell disease in Africa: an urgent need for longitudinal cohort  
526 studies. *The Lancet Global Health*. 2019;7: e1310–e1311. doi:10.1016/S2214-  
527 109X(19)30364-X
- 528 8. 60th Session Regional Committee for Africa. SICKLE-CELL DISEASE: A STRATEGY  
529 FOR THE WHO AFRICAN REGION. Geneva; 2010 pp. 1–7. Available:  
530 <https://apps.who.int/iris/handle/10665/1682>
- 531 9. Piel FB, Rees DC, DeBaun MR, Nnodu O, Ranque B, Thompson AA, et al. Defining global  
532 strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission.  
533 *The Lancet Haematology*. 2023;10. doi:10.1016/S2352-3026(23)00096-0
- 534 10. Piel FB, Hay SI, Gupta S, Weatherall DJ, Williams TN. Global Burden of Sickle Cell  
535 Anaemia in Children under Five, 2010-2050: Modelling Based on Demographics, Excess  
536 Mortality, and Interventions. *PLoS Medicine*. 2013;10. doi:10.1371/journal.pmed.1001484
- 537 11. Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Dewi M, et al. Global  
538 epidemiology of Sickle haemoglobin in neonates: A contemporary geostatistical model-  
539 based map and population estimates. *The Lancet*. 2013;381: 142–151. doi:10.1016/S0140-  
540 6736(12)61229-X
- 541 12. Pule GD, Chimusa ER, Mnika K, Mhandire K, Kampira E, Dandara C, et al. Beta-globin  
542 gene haplotypes and selected Malaria-associated variants among black Southern African  
543 populations. *Global health, epidemiology and genomics*. 2017;2: e17–e17.  
544 doi:10.1017/ghg.2017.14
- 545 13. Barclay G. Sickle cell anaemia in Zambia. *Transactions of the Royal Society of Tropical  
546 Medicine and Hygiene*. 1971;65: 529–30.
- 547 14. Athale UH, Chintu C. The effect of sickle cell anaemia on adolescents and their growth and  
548 development: lessons from the sickle cell anaemia clinic. *Journal of Tropical Pediatrics*.  
549 1994;40: 246–52.
- 550 15. Chindima N, Nkhoma P, Sinkala M, Zulu M, Kafita D, Simakando M, et al. The Use of  
551 Dried Blood Spots: A Potential Tool for the Introduction of a Neonatal Screening Program  
552 for Sickle Cell Anemia in Zambia. *Int J Appl Basic Med Res*. 2018;8: 30–32.
- 553 16. Ministry of Health Zambia. The Zambia Non-Communicable Diseases and Injuries Poverty  
554 Commission Report: Reframing Non-Communicable Diseases & Injuries in Zambia. 2022  
555 pp. 19–19. Available:  
556 [https://static1.squarespace.com/static/55d4de6de4b011a1673a40a6/t/62d0459607789d6c2c  
557 9f4b72/1657816491776/Zambia\\_NCDI+Commission+Report\\_Final..pdf](https://static1.squarespace.com/static/55d4de6de4b011a1673a40a6/t/62d0459607789d6c2c9f4b72/1657816491776/Zambia_NCDI+Commission+Report_Final..pdf)
- 558 17. Makoni M. Newborn screening for sickle cell disease in Africa. *The Lancet Haematology*.  
559 2021;8: e476–e476. doi:10.1016/S2352-3026(21)00166-6
- 560 18. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data  
561 capture (REDCap)-A metadata-driven methodology and workflow process for providing

- 562 translational research informatics support. *Journal of Biomedical Informatics*. 2009;42.  
563 doi:10.1016/j.jbi.2008.08.010
- 564 19. Paintsil V, Ally M, Isa H, Anie KA, Mgaya J, Nkanyemka M, et al. Development of multi-  
565 level standards of care recommendations for sickle cell disease: Experience from  
566 SickleInAfrica. *Frontiers in Genetics*. 2023;13. doi:10.3389/fgene.2022.1052179
- 567 20. Teague S, Youssef GJ, Macdonald JA, Sciberras E, Shatte A, Fuller-Tyszkiewicz M, et al.  
568 Retention strategies in longitudinal cohort studies: A systematic review and meta-analysis.  
569 *BMC Medical Research Methodology*. 2018;18: 1–22. doi:10.1186/s12874-018-0586-7
- 570 21. Robinson KA, Dinglas VD, Sukrithan V, Yalamanchilli R, Mendez-Tellez PA, Dennison-  
571 Himmelfarb C, et al. Updated systematic review identifies substantial number of retention  
572 strategies: Using more strategies retains more study participants. *J Clin Epidemiol*.  
573 2015;68: 1481–1487. doi:10.1016/j.jclinepi.2015.04.013.Updated